American biotech company Lycia Therapeutics priced its initial public offering at $18 per share, at the upper end of the $16-18 per share price range. The company raised $317.5 million through the sale of 17.64 million shares. The stock will be listed and traded on the NASDAQ on October 23, under the ticker symbol “LYCA.” Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities acted as joint bookkeepers for the offering; LifeSci Capital acted as passive bookkeepers for the offering.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.